Bluebird bio

bluebird bio, Inc. (BLUE) Class Action Notice: Robbins LLP Reminds Stockholders of Lead Plaintiff Deadline in Class Action Against bluebird bio, Inc.

Retrieved on: 
Tuesday, April 9, 2024
Sickle cell disease, Biotechnology, Bluebird, Clinical, DSM-IV codes, Patient, History, News, LLP, Cancer, Commercial, Complaint, BLUE, File, SCD, Bluebird bio, FDA, BLA, Food, Person, Pharmaceutical industry

Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Tuesday, April 9, 2024
Certification, Ethics, Complaint, Suite, Bluebird, FDA, Bluebird bio, Security (finance)

Investors who purchased the Company’s securities between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before May 28, 2024.

Key Points: 
  • Investors who purchased the Company’s securities between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before May 28, 2024.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. – BLUE

Retrieved on: 
Monday, April 8, 2024
Sickle cell disease, Patient, History, News, Ext, LLP, Acute myeloid leukemia, Complaint, Pomerantz, Action Replay, Bluebird, Court, Bluebird bio

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE).

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether bluebird and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

ROSEN, A LONGSTANDING LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE

Retrieved on: 
Sunday, April 7, 2024
Titan, Patient, Class, Food and Drug Administration, Advertising, Bluebird, FDA, Court, Bluebird bio, Tobacco

WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Friday, April 5, 2024
Sickle cell disease, Biotechnology, Blue, DSM-IV codes, Patient, History, Class, News, Cancer, Complaint, File, SCD, FDA, BLA, Court, Bluebird bio, Food, Person, Pharmaceutical industry

According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.

Key Points: 
  • According to the Complaint, Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Blue you have until May 28, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

BLUE LAWSUIT ALERT: Levi & Korsinsky Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Retrieved on: 
Thursday, April 4, 2024
Sickle cell disease, Bluebird bio, AML, Telephone, Blue, Patient, History, News, LLP, CLASS, Complaint, NEXT, COST, FDA, Court, Food, Cryptocurrency

NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, April 04, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of bluebird bio investors who were adversely affected by alleged securities fraud between April 24, 2023 and December 8, 2023.
  • Follow the link below to get more information and be contacted by a member of our team:
    BLUE investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

bluebird bio, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – BLUE

Retrieved on: 
Wednesday, April 3, 2024
Sickle cell disease, AML, Blue, Patient, History, News, Complaint, BLUE, Fraud, NEXT, FDA, Bluebird bio, Food, Security (finance)

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE).

Key Points: 
  • NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE).
  • Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

BLUEBIRD BIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc. (NASDAQ: BLUE)

Retrieved on: 
Tuesday, April 2, 2024
Sickle cell disease, Blue, District court, Patient, Food and Drug Administration, News, Cancer, Complaint, Action Replay, Food, FDA, Court, Advertising, Bluebird bio, Security (finance)

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the common stock of bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”).
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected] .
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Tuesday, April 2, 2024
Certification, Ethics, Complaint, Suite, Bluebird, FDA, Bluebird bio, Security (finance)

Investors who purchased the Company’s securities between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before May 28, 2024.

Key Points: 
  • Investors who purchased the Company’s securities between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”), are encouraged to contact the firm before May 28, 2024.
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

ROSEN, NATIONAL TRIAL COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE

Retrieved on: 
Monday, April 1, 2024
Titan, Patient, Class, Food and Drug Administration, Advertising, Bluebird, FDA, Court, Bluebird bio, Tobacco

WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.